Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib

Bruton’s tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-cell survival and proliferation. Designing ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, David Y., Andreotti, Amy H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470882/
https://www.ncbi.nlm.nih.gov/pubmed/37651403
http://dx.doi.org/10.1371/journal.pone.0290872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470882/
https://www.ncbi.nlm.nih.gov/pubmed/37651403
http://dx.doi.org/10.1371/journal.pone.0290872

Ejemplares similares